Cyclic-di-GMP disodium

Research use only, not for human use.

Cyclic-di-GMP disodium (5GP-5GP disodium) is a STING agonist and a second messenger in bacteria.

Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.

Cyclic-di-GMP disodium (0.5-50 μM; 5 days) inhibits proliferation of human colon cancer cells.Cyclic-di-GMP disodium (0.5-50 μM; 5 days) specifically elevates CD4 expression in Jurkat cells.Cyclic-di-GMP disodium (0.5-50 μM; 5 days) induces cell cycle arrest at the S-phase in Jurkat cells.Cell Proliferation Assay Cell Line:H508 cells oncentration:0.5-50 μM Incubation Time:5 days Result:Reduced basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation.Cell Viability Assay Cell Line:Jurkat cells oncentration:50 μM Incubation Time:24 h Result:Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner.Cell Cycle Analysis Cell Line:Jurkat cells Concentration:50 μM Incubation Time:24 h Result:Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which decreased by 93%.

Cyclic-di-GMP disodium (100 μg/per; i.v.; two sequential vaccinations 9 days apart) enhances TriVax-induced immune responses to melanoma in mice and further increased the anti-tumor effects of TriVax.Animal Model:C57BL/6 (B6) mice (8- to 10-week-old).Dosage:100 μg/perAdministration:Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax.Result:Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 μg hgp100 or 100 μg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC).Enhanced the anti-tumor activity of TriVax.

——

Proteasome/Ubiquitin

Endogenous Metabolite

Endogenous Metabolite | STING

——

——

2222132-40-1

734.38

C20H22N10Na2O14P2

>98% (HPLC)

In Vitro:?H2O : 160 mg/mL (217.87 mM; Ultrasonic)

O=C1C2=C(NC(N)=N1)N([C@H]3[C@@H]([C@@]4([H])[C@](COP([O-])(O[C@]5([H])[C@@](O[C@@H](N6C7=C(C(N=C(N7)N)=O)N=C6)[C@@H]5O)([H])COP([O-])(O4)=O)=O)([H])O3)O)C=N2.[Na+].[Na+]

——

(-20℃)

With Ice Pack

≥ 2 years